Fedratinib (Inrebic®). HTA ID: 21069

Assessment Status Rapid Review Complete
HTA ID 21069
Drug Fedratinib
Brand Inrebic®
Indication For the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are JAK inhibitor–naive or have been treated with ruxolitinib.  
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 20/01/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that fedratinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations, December 2022.